MedTrace Logo

A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer

NCT07294508 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 706

Last updated 2026-03-20

No results posted yet for this study

Summary

The study is being conducted to evaluate the clinical efficacy of HLX22 in combination with HLX87 as first-line treatment in patients with HER2-positive recurrent or metastatic breast cancer

Conditions

  • HER2 + Breast Cancer

Interventions

DRUG

HLX87 + HLX22

HLX87 is a novel HER2-targeted ADC with a similar mechanism of action to trastuzumab deruxtecan. HLX22 is a novel monoclonal antibody targeting HER2 .

DRUG

HLX87 + Pertuzumab

HLX87 is a novel HER2-targeted ADC with a similar mechanism of action to trastuzumab deruxtecan

DRUG

T-Dxd + Pertuzumab

T-Dxd is a HER2-targeted ADC

DRUG

THP

Pertuzumab+ Trastuzumab+Docetaxel

Sponsors & Collaborators

Principal Investigators

  • Fei Ma, Dr · Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-27
Primary Completion
2028-01-15
Completion
2030-12-30

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07294508 on ClinicalTrials.gov